Drug
Ropsacitinib clinical trials
Also written PF-06826647.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
6 studies that test it; most in 2019 (3)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 3 |
| 2020 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 0
Often tested with
Tested in the same studies.
Zimlovisertib (1) · PF-06700841 (1) · Contraceptives, Oral (1) · PF-6826647 (1)
Studies
Open first, then newest update. How each study uses ropsacitinib is read from its arms, and is right about nine times in ten.
Testing it · 6
- A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis SuppurativaCompletedPhase 2PfizerNCT04092452Written as PF-06826647
- A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque PsoriasisCompletedPhase 2PfizerNCT03895372Written as PF-06826647
- A Study To Asses Mass Balance And Absolute Bioavailability Of 14C PF-06826647 In Healthy Male ParticipantsCompletedPhase 1PfizerNCT04591262Written as PF-06826647 600 mg PO
- A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative ColitisWithdrawnPhase 2PfizerNCT04209556Written as PF-06826647 100 mg QD
- A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque PsoriasisCompletedPhase 1PfizerNCT03210961Written as PF-06826647 tablet
- A Drug Drug Interaction Study Between PF-06826647 And Oral Contraceptive Steroids In Healthy Female ParticipantsCompletedPhase 1PfizerNCT04134715Written as PF-06826647
Codes
What other systems call ropsacitinib · ClinicalTrials.gg INT001752
- MeSH (NLM) C000720458ropsacitinibOne source NLM
- UNII (FDA) HY5SOV7O0QROPSACITINIBConfirmed FDA, NLM
- NCI Thesaurus C180657RopsacitinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000720458 | ropsacitinib | One source NLM |
| UNII (FDA) | HY5SOV7O0Q | ROPSACITINIB | Confirmed FDA, NLM |
| NCI Thesaurus | C180657 | Ropsacitinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.